辉瑞实验性肺癌药未能提高生存率
2026-06-22 20:42:52
辉瑞表示，其实验性药物sigvotatug vedotin在无法手术治疗的晚期肺癌患者中未能改善生存率，据彭博社报道。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
世界杯 | 姆巴佩达成法国队百场Next article：
21Shares联合创始人：代币化解决结算难题
